EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study

Hiroe Suzuki-Chiba, Takaaki Konishi, Shotaro Aso, Kanako Makito, Hiroki Matsui, Taisuke Jo, Kiyohide Fushimi, Hideo Yasunaga

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02603-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hiroe Suzuki-Chiba und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, …. Hauptthemen laut MEDLINE: Olanzapine, Nausea, Vomiting, Antiemetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Olanzapine is prescribed as prophylaxis for chemotherapy-induced nausea and vomiting at a dose of 2.5 or 5 mg in Asian countries. We compared the effectiveness of olanzapine 2.5 mg and 5 mg in preventing chemotherapy-induced nausea and vomiting among patients receiving high-emetogenic chemotherapy for lung cancer.

Methods

Using a Japanese national inpatient database, we identified patients who received olanzapine doses of 2.5 or 5 mg during high-emetogenic chemotherapy for lung cancer between January 2016 and March 2021. We conducted a 1:1 propensity score-matched analysis with adjustment for various factors, including those affecting olanzapine metabolism. The outcomes were additional antiemetic drug administration (within 2–5 days after chemotherapy initiation), length of hospital stay, and total hospitalization costs.

Results

Olanzapine 2.5 and 5.0 mg were used in 2905 and 4287 patients, respectively. The propensity score-matched analysis showed that olanzapine 2.5 mg administration was significantly associated with a higher proportion of additional antiemetic drug administration (36% vs. 31%, p < 0.001) than olanzapine 5 mg. The median length of hospital stay was 8 days in both groups. Total hospitalization cost did not differ significantly between the two doses of olanzapine (5061 vs. 5160 USD, p = 0.07). The instrumental variable analysis demonstrated compatible results.

Conclusion

Prophylactic use of olanzapine 2.5 mg during chemotherapy for lung cancer was associated with a higher rate of additional antiemetic drugs than olanzapine 5 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineNauseaVomitingAntiemeticsDatabases, FactualLung NeoplasmsHumansFemaleMaleMiddle AgedJapanAgedLength of StayAntineoplastic AgentsPropensity ScoreAdultRetrospective StudiesEast Asian People

Stichwörter der Autor:innen

AntiemeticsChemotherapyCisplatinLung cancerOlanzapine

Substanzen

OlanzapineAntiemeticsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. hiroechiba@m.u-tokyo.ac.jp.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
  • Department of Real World Evidence, Graduates School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, The University of Tokyo, Tokyo, Japan.

Förderung

  • Ministry of Health, Labour and Welfare
  • The University of Tokyo

Zitieren

APA

Suzuki-Chiba, H., Konishi, T., Aso, S., Makito, K., Matsui, H., Jo, T., Fushimi, K., & Yasunaga, H. (2024). Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02603-2

Vancouver

Suzuki-Chiba H, Konishi T, Aso S, Makito K, Matsui H, Jo T, et al. Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02603-2

BibTeX
@article{SuzukiChiba2024,
  author = {Suzuki-Chiba, Hiroe and Konishi, Takaaki and Aso, Shotaro and Makito, Kanako and Matsui, Hiroki and Jo, Taisuke and Fushimi, Kiyohide and Yasunaga, Hideo},
  title = {Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02603-2}
}
Kostenlos starten →